LuciCaboz 20 MG (Cabozantinib)

Basic Product Information of LuciCaboz 20 MG (Cabozantinib)

How LuciCaboz 20 MG (Cabozantinib) Works: Multitargeted Kinase Inhibition Across MET, VEGFR, RET, AXL, and Multiple Oncogenic Drivers

Cabozantinib INN is an orally bioavailable small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) that function as critical oncogenic drivers across kidney, liver, thyroid, and other solid malignancies. Unlike single-target kinase inhibitors, cabozantinib simultaneously blocks the ATP-binding kinase domains of MET (hepatocyte growth factor receptor; HGFR), VEGFR-1, VEGFR-2, VEGFR-3, RET, AXL, KIT, TRKB, FLT-3, TYRO3, MER, ROS1, and TIE-2 a portfolio of targets spanning tumor angiogenesis, tumor cell proliferation, invasiveness, immune evasion, and the primary resistance mechanisms that emerge after first-line anti-VEGF therapies.

By inhibiting all three VEGF receptors simultaneously, cabozantinib blocks the full complement of vascular endothelial growth factor (VEGF)-driven neovascularization that tumors require for oxygen and nutrient supply, suppressing tumor angiogenesis more completely than agents targeting VEGFR-2 alone. Concurrent MET inhibition is clinically critical because MET pathway activation is the dominant adaptive resistance mechanism that tumor cells deploy when VEGFR signaling is blocked by first-line anti-VEGF therapies meaning that patients who have progressed on prior VEGFR-targeted drugs frequently harbor tumors with upregulated MET signaling, which cabozantinib addresses directly alongside its continued anti-VEGFR activity.

AXL inhibition adds a further mechanistic dimension that distinguishes cabozantinib from earlier-generation TKIs: AXL is a receptor tyrosine kinase overexpressed in multiple solid tumors and implicated in epithelial-to-mesenchymal transition (EMT), tumor immune evasion (through suppression of NK cell and dendritic cell function), and acquired resistance to VEGFR-targeted drugs and immune checkpoint inhibitors. By blocking AXL alongside MET and VEGFR, cabozantinib disrupts three mechanistically distinct but clinically convergent resistance pathways simultaneously.

RET inhibition is the defining mechanism of cabozantinib’s activity in thyroid cancers: activating mutations and rearrangements in the RET proto-oncogene are the primary oncogenic drivers in medullary thyroid cancer (MTC), occurring in approximately 60% of sporadic MTC and nearly all hereditary MTC cases, and RET rearrangements also drive a subset of papillary and differentiated thyroid cancers. Cabozantinib’s RET kinase inhibition directly targets the driver mutation in these tumors, blocking constitutive RET signaling that would otherwise drive continuous tumor cell proliferation.

In renal cell carcinoma, the combination of MET, VEGFR, and AXL inhibition all three pathways simultaneously active in the post-anti-VEGF progressed tumor microenvironment accounts for cabozantinib’s superiority over everolimus (an mTOR inhibitor) in the METEOR Phase 3 trial, where cabozantinib addressed resistance mechanisms that everolimus does not target. For a comprehensive range of targeted oncology medicines across tumor types, visit the Mediaid Pharmacy oncology medicines collection.

Cabozantinib is extensively bound to plasma proteins (≥99.7%) and has a long plasma half-life of approximately 55 hours, which supports once-daily oral dosing and maintains sustained target inhibition throughout the 24-hour dosing interval. Cabozantinib is metabolized primarily through CYP3A4; co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, grapefruit and grapefruit juice) increases cabozantinib plasma exposure and requires a 20 mg dose reduction, while co-administration with strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s Wort) reduces cabozantinib exposure and requires a 20 mg dose increase if the combination cannot be avoided the precise 20 mg tablet format of LuciCaboz 20 MG enables both of these structured adjustments from the standard 60 mg dose without requiring a separate tablet strength.

LuciCaboz 20 MG (Cabozantinib): Indications, Dosing, and Key Safety Information

Dose Reduction StepsStarting dose 60 mg → First reduction 40 mg → Second reduction 20 mg → Permanently discontinue if 20 mg once daily is not tolerated.Pregnancy & LactationCabozantinib may cause embryo-fetal harm and is not recommended during pregnancy.

Who Should Use LuciCaboz 20 MG (Cabozantinib)?

LuciCaboz 20 MG (Cabozantinib) is indicated across four distinct oncology patient populations, each defined by a specific cancer type and prior treatment history making cabozantinib one of the most broadly indicated targeted oncology agents across multiple tumor types. First, adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy constitute the primary established indication specifically patients who have progressed on a prior VEGFR-targeted therapy (such as sunitinib, pazopanib, or axitinib) and for whom cabozantinib demonstrated a 42% reduction in the risk of disease progression or death and a near-doubling of median PFS (7.4 months vs. 3.8 months with everolimus) in the METEOR Phase 3 trial.

Cabozantinib is also approved in combination with nivolumab as a first-line option for treatment-naïve advanced RCC in selected patients. Second, adult patients with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib the HCC second-line indication established by the CELESTIAL Phase 3 trial, where cabozantinib extended median OS to 10.2 months versus 8.0 months with placebo, and more than doubled median PFS to 5.2 months versus 1.9 months. Third, adult patients with progressive metastatic medullary thyroid cancer (MTC) the RET-driven thyroid malignancy for which cabozantinib’s simultaneous RET and MET inhibition provides targeted blockade of the primary oncogenic driver, particularly in patients with sporadic or hereditary MTC harboring RET mutations. Fourth, adult patients with radioactive iodine-refractory differentiated thyroid cancer (DTC) who have progressed following prior VEGFR-targeted therapy, for whom cabozantinib provides a second-line targeted option.

LuciCaboz 20 MG is contraindicated or requires careful benefit-risk assessment in patients with uncontrolled hypertension, recent major surgery (within 3 months, due to wound healing complications), active GI bleeding or fistulas, severe hepatic impairment, or confirmed hypersensitivity to cabozantinib or any excipient. Thyroid function monitoring is recommended prior to and during treatment, particularly in MTC and DTC patients. The treating oncologist must conduct a full medication review before initiating LuciCaboz 20 MG to identify strong CYP3A4 inhibitors or inducers requiring dose adjustment. Oncology centers sourcing LuciCaboz 20 MG alongside complementary targeted therapies for RCC, HCC, or thyroid cancers can browse the Mediaid Pharmacy kidney cancer medicines and liver cancer medicines portfolios for a comprehensive selection of agents available for international delivery.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciCaboz 20 MG (Cabozantinib)

Mediaid Pharmacy is a Dhaka-based supplier of specialty oncology and precision medicine products with worldwide shipping to patients, oncology clinics, cancer hospitals, and international distributors across all regions. LuciCaboz 20 MG (Cabozantinib), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as 90 film-coated tablets of 20 mg per pack a complete 30-day treatment supply at the standard 60 mg once-daily dose with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.

The 20 mg tablet format covers all three approved dose levels of the cabozantinib tablet reference label (60 mg, 40 mg, and 20 mg), allowing oncology programs to manage dose modifications from a single pack without requiring multiple product SKUs. Urological oncology centers treating advanced RCC, gastrointestinal oncology programs treating advanced HCC, endocrinology and thyroid oncology clinics treating MTC and DTC, hospital formulary teams, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciCaboz 20 MG Cabozantinib stock availability, current pricing, and international delivery timelines.

Procurement teams co-sourcing LuciCaboz 20 MG with other targeted oncology agents including combination partners for first-line advanced RCC protocols, or a comprehensive solid-tumor oncology formulary can browse the complete Mediaid Pharmacy oncology medicines collection and the Lucius Pharmaceuticals medicines portfolio before requesting a consolidated quotation.

Why Choose LuciCaboz 20 MG (Cabozantinib) from Mediaid Pharmacy?

LuciCaboz 20 MG (Cabozantinib) provides medical oncologists, urological oncologists, gastrointestinal oncologists, and endocrine oncologists with a multi-indication, multitargeted TKI that has demonstrated Phase 3-level efficacy across four distinct solid tumor types a clinical breadth that is uncommon among approved targeted oncology agents and that reflects cabozantinib’s mechanism of simultaneously blocking the convergent resistance pathways (MET, AXL) alongside the primary angiogenic drivers (VEGFR-1, -2, -3) that single-target anti-VEGF agents fail to address after first-line treatment.

The pivotal Phase 3 data a 42% reduction in disease progression risk versus everolimus in previously treated advanced RCC (METEOR), and a statistically significant OS benefit of 10.2 versus 8.0 months in sorafenib-pretreated HCC (CELESTIAL) establish LuciCaboz 20 MG as a clinically validated option in precisely defined second-line patient populations where outcomes with prior standard therapies are poor. The 20 mg tablet design of LuciCaboz 20 MG is a clinically rational formulation choice: because cabozantinib’s dose modification schedule reduces the starting 60 mg dose in 20 mg decrements (to 40 mg and then 20 mg), the 20 mg tablet unit enables oncology pharmacists to implement all three approved dose levels from a single product pack three tablets for the starting dose, two tablets for the first reduction, and one tablet for the maximum reduction without dispensing multiple tablet strengths or repackaging.

The 90-tablet pack size aligns precisely to a 30-day supply at the 60 mg starting dose, simplifying monthly procurement planning for oncology centers and international patients receiving LuciCaboz 20 MG outside the originator brand’s distribution network. LuciCaboz 20 MG is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source Lucius Pharmaceuticals oncology medicines, additional kidney cancer, liver cancer, or thyroid cancer targeted agents, visit the Mediaid Pharmacy Lucius Pharmaceuticals medicines section and the thyroid cancer medicines portfolio, and contact the team for a personalized quotation.

Frequently Asked Questions About LuciCaboz 20 MG (Cabozantinib)